Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
6(27%)
Results Posted
38%(3 trials)

Phase Distribution

Ph phase_3
1
5%
Ph phase_2
5
23%
Ph phase_1
1
5%
Ph phase_4
4
18%
Ph not_applicable
4
18%
Ph early_phase_1
2
9%

Phase Distribution

3

Early Stage

5

Mid Stage

5

Late Stage

Phase Distribution17 total trials
Early Phase 1First-in-human
2(11.8%)
Phase 1Safety & dosage
1(5.9%)
Phase 2Efficacy & side effects
5(29.4%)
Phase 3Large-scale testing
1(5.9%)
Phase 4Post-market surveillance
4(23.5%)
N/ANon-phased studies
4(23.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

6

trials recruiting

Total Trials

22

all time

Status Distribution
Active(7)
Completed(8)
Terminated(1)
Other(6)

Detailed Status

Completed8
unknown6
Recruiting6
Not yet recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (11.8%)
Phase 11 (5.9%)
Phase 25 (29.4%)
Phase 31 (5.9%)
Phase 44 (23.5%)
N/A4 (23.5%)

Trials by Status

not_yet_recruiting15%
unknown627%
withdrawn15%
completed836%
recruiting627%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT05227937

Single Dose Amikacin for Uncomplicated Cystitis in the ED: A Feasibility Study

Recruiting
NCT06426836Not Applicable

Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)

Recruiting
NCT00042289

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Completed
NCT03825874

Research of the Consequences on the Digestive Tract Following the Proposed Treatments for a Urinary Infection in Children

Recruiting
NCT04310930Phase 2

Finding the Optimal Regimen for Mycobacterium Abscessus Treatment

Recruiting
NCT06602557Phase 2

" a Randomized Pilot Study of the Benefit of Nebulized Amikacin in the Treatment of Gram-negative Bacillus Pneumonia Acquired During Mechanical Ventilation in Patients Receiving Extracorporeal Membrane Veno-arterial Oxygenation (ECMO-VA)."

Not Yet Recruiting
NCT05761405Early Phase 1

Potentiated Aminoglycosides in Postoperative Urinary Tract Infection Prophylaxis

Recruiting
NCT06097767Early Phase 1

the Incidence of Necrotizing Enterocolitis in Preterm With Respiratory Distress Syndrome Undergoing Caffeine Therapy

Unknown
NCT04209192Phase 2

Antimicrobial Prophylaxis in Patients Who Underwent a Transurethral Resection of Bladder (TURB)

Completed
NCT05555303Phase 2

Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis

Recruiting
NCT04470973

Pharmacokinetics of Amikacin and Cefuroxime in Critically Ill Patients.

Unknown
NCT04132115

Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)

Unknown
NCT04867993Not Applicable

Amikacin Pharmacokinetics to Optimize Dosing Recommendations in Neonates With Perinatal Asphyxia Treated With Hypothermia

Unknown
NCT04197739Phase 4

Fixed-dose Amikacin for Elderly UTI

Unknown
NCT01659866Phase 4

Antibiotic Prophylaxis for Transrectal Prostate Biopsy

Completed
NCT02081963Phase 4

Combined Administration of Nebulized Amikacin in Patients With Acute Exacerbation of Non-Cystic Fibrosis Bronchiectasis

Completed
NCT02574130Not Applicable

Effect of Additional Nebulized Amikacin in Ventilator-Associated Pneumonia Caused by Gram Negative Bacteria

Completed
NCT02897869Phase 1

DDI Study to Investigate Interaction Between Amikacin and POL7080

Completed
NCT02489955Not Applicable

Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis

Unknown
NCT02365272Phase 4

Pharmacokinetic/Pharmacodynamic Evaluation Amikacin in Critically Ill Patients Admitted at the Emergency Department

Completed

Drug Details

Intervention Type
OTHER
Total Trials
22